Dr. Jing Fan, founder of Hopstem Biotechnology Co.,Ltd. She received her bachelor’s degree at Peking University, Ph.D in Neuroscience at UBC, and postdoctoral training in Neurology and Institute of Cell Engineering of Johns Hopkins University. Since 2017, Dr. Fan has devoted to developing the most cutting-edge iPSC and cell engineering technologies and products to promote drug discovery and cell therapy for stroke, TBI, autism, AD, ALS and other diseases.

Dr. Fan has published more than 10 academic papers and book chapters on top journals. Her main expertise are pluripotent stem cells, neural differentiation, with more than 17 years of experience in neuroscience, cell signaling pathway and drug discovery. She has led the Hopstem team and established a platform with PCT protected patents, GMP iPSC line, cell bank and continuous pipelines. Hopstem has received 5 rounds of financing funds, started a new GMP manufactory facility, and expanded to other disease areas with collaborations. Several clinical products are under development with the fastest one expected for IND application by the end of 2022. Dr. Fan has been elected as one of the “30 Global Innovative talents of Chinese entrepreneurs” in 2018.